Visceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas

Simon L. Barry; Emer Lynch; Philip Bredin; Sebastian McWilliams; Julie McCarthy; Orla O’Mahony; Linda Feeley; Killian Nugent; Patrick Sheahan; Deirdre O’Hanlon; David O’Reilly; Seamus O’Reilly

doi:10.3390/onco4040030

Onco (Dec 2024)

Visceral Perforation Complicating BRAF/MEK Targeted Therapy of Papillary Thyroid Carcinoma with Anaplastic Areas

Simon L. Barry,
Emer Lynch,
Philip Bredin,
Sebastian McWilliams,
Julie McCarthy,
Orla O’Mahony,
Linda Feeley,
Killian Nugent,
Patrick Sheahan,
Deirdre O’Hanlon,
David O’Reilly,
Seamus O’Reilly

Affiliations

Simon L. Barry: Department of Medical Oncology and UCC Cancer Clinical Trials Group, Cork University Hospital, Cork, Ireland
Emer Lynch: Department of Medical Oncology and UCC Cancer Clinical Trials Group, Cork University Hospital, Cork, Ireland
Philip Bredin: Department of Medical Oncology and UCC Cancer Clinical Trials Group, Cork University Hospital, Cork, Ireland
Sebastian McWilliams: Department of Radiology, South Infirmary Victoria University Hospital, Cork, Ireland
Julie McCarthy: Department of Histopathology, South Infirmary Victoria University Hospital, Cork, Ireland
Orla O’Mahony: Department of Histopathology, South Infirmary Victoria University Hospital, Cork, Ireland
Linda Feeley: Department of Histopathology, South Infirmary Victoria University Hospital, Cork, Ireland
Killian Nugent: Department of Radiotherapy, Cork University Hospital, Cork, Ireland
Patrick Sheahan: ENTO Research Unit, School of Medicine and Health, University College Cork, Cork, Ireland
Deirdre O’Hanlon: Department of General/Breast Surgery, South Infirmary Victoria University Hospital, Cork, Ireland
David O’Reilly: Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland
Seamus O’Reilly: Department of Medical Oncology and UCC Cancer Clinical Trials Group, Cork University Hospital, Cork, Ireland

DOI: https://doi.org/10.3390/onco4040030
Journal volume & issue: Vol. 4, no. 4
pp. 427 – 438

Abstract

Read online

Anaplastic thyroid cancer (ATC) is considered to be one of the most virulent, treatment-refractory malignancies. Recent molecular insights into the biology of thyroid cancer have transformed ATC management, and BRAF/MEK targeted therapy is now incorporated into guideline-based multidisciplinary care. We report visceral perforation in the setting of an extreme response to such therapy in a patient with ATC. Molecularly targeted therapy afforded a dramatic but life-threatening response to treatment. This report highlights the complexities of care for the patient and treating clinicians.

Published in Onco

ISSN: 2673-7523 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/onco

About the journal

Abstract

Keywords